Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Revolutionary New Tool Developed at Saint Luke's Uses Personalized Medicine to Evaluate Stroke Patients for Clot-busting Drug tPA
  • USA - English


News provided by

Saint Luke's Health System

Mar 07, 2016, 09:00 ET

Share this article

Share toX

Share this article

Share toX

John A. Spertus, M.D., M.P.H.
John A. Spertus, M.D., M.P.H.
Youtube
Youtube

Kansas City, MO (PRWEB) March 07, 2016 -- During a stroke, time saved equals brain cells saved, so every second counts when it comes to receiving treatment. The clot-busting medication tissue plasminogen activator (tPA) has proven to be one of the most effective treatments for ischemic stroke. However, tPA is not administered to those having a stroke as often or as quickly as it could be, due to the real concern that despite its ability to reverse stroke, tPA given to the wrong patient could cause dangerous bleeding.

What is really needed is a way to show-for an individual stroke patient-whether administering tPA gives them the likelihood for a positive outcome.

Post this

“Some emergency room doctors feel the benefits of tPA far outweigh the risks. Others feel the risks far outweigh the benefits,” said John A. Spertus, M.D., M.P.H., director of Saint Luke’s Mid America Heart Institute’s Cardiovascular Outcomes Research program. “What is really needed is a way to show–for an individual patient–whether administering tPA gives them the likelihood for a positive outcome.”

To provide a risk/benefit analysis quickly for Emergency Department physicians, Saint Luke’s, Tufts University, and UCLA, through the American Heart Association’s Outcomes Research Center Initiative, collaborated to develop a tool based on data/evidence-based research that estimates within moments a specific patient’s most likely 90-day outcome with and without tPA administration.

Rapid Evaluation for Stroke Outcomes using Lytics in Vascular Event, or RESOLVE, is a revolutionary tool that uses an individual patient’s data to generate a risk/benefit analysis report detailing the most likely outcome of receiving tPA. The report provides emergency room physicians with hard, true evidence and fact-based data, enabling the physician, the patient, and their family to make the most well-informed and expedited decision. Research involved in developing RESOLVE looked at data from more than 2,100 patients from five randomized clinical trials, verified in a sixth trial.

RESOLVE supports and accelerates medical decision-making by reviewing six patient-specific clinical variables:
• Last time known well
• Age
• Systolic BP
• Diabetes
• Current glucose
• Stroke severity (level of consciousness, gaze, weakest limb)
• 0 graded = normal
• 1 graded = mild impairment
• 2 graded = severe impairment

If administered within three hours, and up to 4.5 hours in certain eligible patients, tPA may improve patients’ chances of recovering from stroke. A good outcome means functional independence at 90 days (a modified Rankin of 0-2). A bad outcome means severe disability or death at 90 days (a modified Rankin of 5-6). The earlier tPA is properly administered, the more brain cells may be saved, and the more likely a patient will have a better outcome after treatment.

The Comprehensive Stroke Program at Saint Luke’s Marion Bloch Neuroscience Institute began using the RESOLVE tool in November 2015. Saint Luke’s envisions this tool will be most useful to physicians at Emergency Departments that treat a limited number of stroke patients, enabling them to bring the patient and family into an expedited decision-making process and make decisions that will result in better patient outcomes. Currently, referring physicians may access a consulting neurologist and the RESOLVE tool by contacting Doctors’ One Call at Saint Luke’s Marion Bloch Neuroscience Institute.

“This is evidence-based medicine that provides a roadmap for each individual patient, and should be very helpful in making the right decisions,” said Karin E. Olds, M.D., stroke program director at Saint Luke’s Marion Bloch Neuroscience Institute. “Our challenge is creating demand for this kind of tool. When physicians are ready for such tools to help with stroke care, RESOLVE is a perfect solution for them.”

Saint Luke’s receives stroke patients from more than 80 hospitals in the Kansas City, Mo. region. When a patient’s originating hospital accurately diagnoses and begins stroke treatment prior to transfer, long-term outcomes improve dramatically.

Signs and symptoms of a stroke include:
• Sudden weakness on one side of the body
• Sudden numbness on one side of the body
• Sudden loss of vision – especially in one eye
• Sudden difficulty speaking or understanding
• Sudden severe headache

Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI) is a comprehensive center for neuroscience research, education, and evidence-based medicine that combines faculty in neurology, neurosurgery, interventional neuroradiology, neurootology, psychiatry, and physical medicine and rehabilitation. Together SLMBNI faculty provides patient-centered leading-edge care to thousands of patients from all over the country each year. As a member of Saint Luke’s Health System, SLMBNI is a global leader in utilizing both drug and mechanical interventions to reverse the permanent and debilitating effects of ischemic stroke. Its legacy of innovation began in 1993 when doctors performed one of the world’s first intra-arterial stroke reversal procedures. Since then, Saint Luke’s specialists have continued to pioneer new stroke treatments and reverse strokes in thousands of patients through its network of stroke centers. Located in Kansas City, Mo., SLMBNI brings together a team of highly specialized neuroscientists to provide comprehensive treatment for the most complex neurological diseases, including stroke, epilepsy, brain tumors, Parkinson’s and Alzheimer’s diseases, multiple sclerosis, headaches and facial pain, as well as aneurysms and intracerebral hemorrhages. The Institute’s multispecialty team provides the latest in minimally invasive spinal surgical techniques for the treatment of acute and chronic back pain. SLMBNI strives to be a national leader in neurological treatment and care by advancing clinical research and evidence-based clinical practice.

Saint Luke’s Health System consists of 10 area hospitals and several primary and specialty care practices, and provides a range of inpatient, outpatient, and home care services. Founded as a faith-based, not-for-profit organization, our mission includes a commitment to the highest levels of excellence in health care and the advancement of medical research and education. The health system is an aligned organization in which the physicians and hospitals assume responsibility for enhancing the physical, mental, and spiritual health of people in the metropolitan Kansas City area and the surrounding region.

Michelle Manuel, Saint Luke's Health System, +1 (816) 502-8533, [email protected]

Modal title

Karin Olds, M.D., medical director of SLMBNI Comprehensive Stroke Program
Karin Olds, M.D., medical director of SLMBNI Comprehensive Stroke Program
Karin Olds, M.D., medical director of SLMBNI Comprehensive Stroke Program

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.